ACADIA PHARMACEUTICALS INC 4

EVP & CFO Mark C. Schneyer exercised options and sold 20,141 ACADIA Pharmaceuticals (ACAD) shares around $29 per share in cashless transactions under a Rule 10b5-1 plan.

On August 5–6, 2026, ACADIA Pharmaceuticals’ EVP and CFO, Mark C. Schneyer, exercised stock options for a total of 20,141 shares of common stock at an exercise price of $17.84 per share and sold an equivalent 20,141 shares in market transactions around $29 per share under a pre-established Rule 10b5-1 trading plan. On August 5 he exercised options for 5,849 shares and sold all 5,849 shares at a weighted average price of $29.0029; on August 6 he exercised options for 14,292 shares and sold 5,000 shares at $29.00 and 9,292 shares at a weighted average price of $29.3375. These trades appear to be largely cashless exercises associated with previously granted options that vest over time, and after the transactions he continued to hold 67,828 shares of ACADIA common stock, including shares accumulated via the company’s employee stock purchase plan.

Filing Facts

CIK

1070494

Ticker

ACAD

Form

4

Source Type

fda

Accession

0001899977-26-000008

Alert Tier

6